The first Chaperone Therapy for Fabry patients.
Excited to share Health Canada’s approval of the oral- precision medicine Galafold! We look forward to this differentiated treatment option for Canadian patients with amenable mutations. Please see the press release for further information.
Subscribe error, please review your email address.Close
You're now subscribed, thank you!Close
There was a problem with your submission. Please check the field(s) with red label below.Close
Your message has been sent. We'll get back to you soon!Close